Boehringer Ingelheim has extended research funding for another year in its Alzheimer's disease collaboration with Ablynx. In January 2007 the companies entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, a class of therapeutic proteins. The agreement included a joint research program with Ablynx scientists.

BI will be responsible for the development, manufacture and commercialization of any products resulting from the collaboration. As part of the collaboration, Ablynx received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales.
   
Dr. Edwin Moses, chief executive officer and chairman of Ablynx, commented, "We are very pleased with the progress that has been made in our joint Alzheimer's disease program with BI. We look forward to continue working together with BI in this medical area which urgently requires an innovative approach."

News from our sister sites